Intronic sequence variants of the CDKN2A gene in melanoma pedigrees

Genes Chromosomes and Cancer

Volumn 43, Issue 2, 2005, Pages 128-136

  Harland, Mark ^a   Taylor, Claire F ^a   Bass, Sylvia ^a   Churchman, Michael ^b   Randerson Moor, Juliette A ^a   Holland, Elizabeth A ^c   Mann, Graham J ^c   Bishop, D Timothy ^a   Newton Bishop, Julia A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P14ARF; PROTEIN P16INK4A;

ARTICLE; CANCER SCREENING; CDKN2A GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MELANOMA; NUCLEOTIDE SEQUENCE; PEDIGREE; PRIORITY JOURNAL; RNA SPLICING; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; DNA PRIMERS; FEMALE; GENES, P16; GERM-LINE MUTATION; HUMANS; INTRONS; MALE; MELANOMA; PEDIGREE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING;

EID: 17644384830     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20177     Document Type: Article

References (47)

1. Bennett DC, Medrano EE. 2002. Molecular regulation of melanocyte senescence. Pigment Cell Res 15:242-250.
2. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W, Peters G. 2002. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. Embo J 21:2936-2945.
3. Burrows NP, Nicholls AC, Richards AJ, Luccarini C, Harrison JB, Yates JR, Pope FM. 1998. A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families. Am J Hum Genet 63:390-398.
4. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-de Paillerets B, Goldstein AM. 2000. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 67:311-319.
5. Dracopoli NC, Fountain JW. 1996. CDKN2 mutations in melanoma. Cancer Surv 26:115-132.
6. Fairbrother WG, Yeh RF, Sharp PA, Burge CB. 2002. Predictive identification of exonic splicing enhancers in human genes. Science 297:1007-1013.
7. Flores JF, Pollock PM, Walker GJ, Glendening JM, Lin AH, Palmer JM, Walters MK, Hayward NK, Fountain JW. 1997. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 15:2999-3005.
8. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. 1997. The CDKN2A (p16) gene and human cancer. Mol Med 3:5-20.
9. Goldstein AM, Tucker MA. 1997. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 89:676-678.
10. Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP. 2001. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. Br J Cancer 85:527-530.
11. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR. 1995. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351-353.
12. Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Newton Bishop J. 1997. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061-2067.
13. Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BA, Mann GJ, Bishop DT, Newton Bishop J. 2000. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 28:45-57.
14. Harland M, Mistry S, Bishop DT, Newton Bishop JA. 2001. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10:2679-2686.
15. Hashemi J, Bendahl PO, Sandberg T, Platz A, Linder S, Stierner U, Olsson H, Ingvar C, Hansson J, Borg A. 2001. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes Cancer 31:107-116.
16. Hayward NK. 1996. The current situation with regard to human melanoma and genetic inferences. Curr Opin Oncol 8:136-142.
17. Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N. 2002. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 11:1273-1279.
18. Hilleren PJ, Parker R. 2003. Cytoplasmic degradation of splicedefective pre-mRNAs and intermediates. Mol Cell 12:1453-1465.
19. Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, Kefford RF, Mann GJ. 1995. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11:2289-2294.
20. Holland EA, Schmid H, Kefford RF, Mann GJ. 1999. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 25:339-348.
21. Huot TJ, Rowe J, Harland M, Drayton S, Brookes S, Gooptu C, Purkis P, Fried M, Bataille V, Hara E, Newton Bishop J, Peters G. 2002. Biallelic mutations in p16(INK4a) confer resistance to Rasand Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol 22:8135-8143.
22. Janssen RJ, Wevers RA, Haussler M, Luyten JA, SteenbergenSpanjers GC, Hoffmann GF, Nagatsu T, Van den Heuvel LP. 2000. A branch site mutation leading to aberrant splicing of the human tyrosine hydroxylase gene in a child with a severe extrapyramidal movement disorder. Ann Hum Genet 64:375-382.
23. Jones AC, Austin J, Hansen N, Hoogendoorn B, Oefner PJ, Cheadle JP, O'Donovan MC. 1999. Optimal temperature selection for mutation detection hy denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin Chem 45:1133-1140.
24. King K, Flinter FA, Nihalani V, Green PM. 2002. Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet 111:548-554.
25. Krawczak M, Reiss J, Cooper DN. 1992. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 90:41-54.
26. Lee LG, Connell CR, Bloch W. 1993. Allelic discrimination by nicktranslation PCR with fluorogenic probes. Nucleic Acids Res 21:3761-3766.
27. Li M, Pritchard PH. 2000. Characterization of the effects of mutations in the putative branchpoint sequence of intron 4 on the splicing within the human lecithin:cholesterol acyltransferase gene. J Biol Chem 275:18079-18084.
28. Liggett WH Jr., Sidransky D. 1998. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16:1197-1206.
29. Liu L, Goldstein AM, Tucker MA, Brill H, Gruis NA, Hogg D, Lassam NJ. 1997. Affected members of melanoma-prone families with linkage to 9p21 hut lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosomes Cancer 19:52-54.
30. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. 1999. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128-132.
31. Loo JC, Liu L, Hao A, Gao L, Agatep R, Shennan M, Summers A, Goldstein AM, Tucker MA, Deters C, Fusaro R, Blazer K, Weitzel J, Lassam N, Lynch H, Hogg D. 2003. Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene 22:6387-6394.
32. Mayer K, Ballhausen W, Leistner W, Rott H. 2000. Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences. Biochim Biophys Acta 1502:495-507.
33. McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao QY, Lennox GG, Taylor MR. 1996. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 59:320-330.
34. Newton Bishop JA, Harland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, Ponder BA, Cuzick J, Selby P, Bishop DT 1999. Mutation testing in melanoma families: INK4A, CDK4 and INK4D. Br J Cancer 80:295-300.
35. Pagani F, Baralle FE. 2004. Genomic variants in exons and intron: identifying the splicing spoilers. Nat Rev Genet 5:389-396.
36. Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M. 2001. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosomes Cancer 31:398-401.
37. Platz A, Hansson J, Ringborg U. 1998. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 78:13-15.
38. Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK. 1998. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 11:424-431.
39. Pollock PM, Stark MS, Palmer JM, Walters MK, Aitken JF, Martin NG, Hayward NK. 2001. Mutation analysis of the CDKN2A promoter in Australian melanoma families. Genes Chromosomes Cancer 32:89-94.
40. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton Bishop J, Bishop DT. 2001. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10:55-62.
41. Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jimenez L, Mila M, Kefford RF. 2001a. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20:5543-5547.
42. Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF. 2001b. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276:41424-41434.
43. Roussel MF. 1999. The INK4 family of cell cycle inhibitors in cancer. Oncogene 18:5311-17.
44. Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP. 2003. CDKN2A point mutations D153spl(c.457G > T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene 22:4444-4448.
45. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B. 1998. Prevalence of p16 and CDK4 germline mutations in 48 melanomaprone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209-216.
46. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A. 1995. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988-2994.
47. Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlow SJ, Easty DJ, Cheong SC, Beach D, DePinho RA, Bennett DC. 2002. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 94:446-454.